Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Acute Myeloid Leukemia
100%
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
55%
Venetoclax
51%
Newly Diagnosed
44%
Chronic Myeloid Leukemia
40%
Phase I Study
32%
Myelofibrosis
30%
Complete Remission
27%
Myeloproliferative Neoplasms
26%
Overall Survival
26%
Hypomethylating Agents
24%
CD123
23%
Ruxolitinib
22%
Myelodysplastic Syndrome
22%
Tagraxofusp
22%
Relapsed/refractory Acute Myeloid Leukemia
22%
Patient Outcomes
18%
Azacitidine
16%
Relapsed/refractory
16%
Phase II Trial
16%
Median Overall Survival
16%
Intensive Chemotherapy
15%
Decitabine
15%
Targeted Therapy
14%
Cytarabine
14%
Older Patients
13%
High Risk
12%
Polycythemia Vera
12%
Leukemia
12%
Hematological Malignancies
11%
Clinical Outcomes
11%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
11%
FMS-like Tyrosine Kinase 3 (FLT3)
11%
Higher-risk Myelodysplastic Syndromes
10%
Single Center
10%
Minimal Residual Disease
10%
Tyrosine Kinase Inhibitor
10%
Event-free Survival
10%
Patient Characteristics
10%
Frontline Therapy
9%
Dasatinib
9%
Bone Marrow
9%
Monotherapy
9%
Clinical Trials
9%
Gemtuzumab Ozogamicin
9%
Cladribine
9%
Idarubicin
9%
Leukemia Patients
9%
Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia
9%
Older Adults
8%
Medicine and Dentistry
Acute Myeloid Leukemia
91%
Neoplasm
50%
Venetoclax
46%
Plasmacytoid Dendritic Cell
42%
Overall Survival
42%
Diseases
30%
Chemotherapy
28%
Myeloproliferative Neoplasm
28%
Myelodysplastic Syndrome
27%
Myelofibrosis
26%
Hypomethylating Agent
21%
Cytarabine
20%
Chronic Myelogenous Leukemia
18%
Ruxolitinib
18%
Azacitidine
16%
Tagraxofusp
16%
Acute Lymphoblastic Leukemia
16%
Clinical Trial
15%
Philadelphia 1 Chromosome
14%
Polycythemia vera
13%
Decitabine
13%
Arm
13%
Adverse Event
12%
Acute Myelogenous Leukemia
12%
Low Drug Dose
12%
Chronic Myelomonocytic Leukemia
12%
Cancer
11%
Tyrosine-Kinase Inhibitor
10%
Adolescence
10%
Minimal Residual Disease
10%
Targeted Therapy
10%
Leukemia
9%
Malignant Neoplasm
9%
Event Free Survival
8%
Hematologic Malignancy
8%
Cladribine
8%
Genetics
8%
Dasatinib
8%
Myeloid Leukemia
7%
Cyclophosphamide
7%
Janus Kinase Inhibitor
7%
Social Media
7%
Ponatinib
7%
Vincristine
7%
Idarubicin
6%
B-Cell Chronic Lymphocytic Leukemia
6%
Oncology
6%
Monotherapy
6%
Dexamethasone
6%
Fludarabine
6%
Pharmacology, Toxicology and Pharmaceutical Science
Acute Myeloid Leukemia
67%
Neoplasm
32%
Venetoclax
31%
Overall Survival
22%
Remission
21%
Myelodysplastic Syndrome
20%
Chemotherapy Regimen
20%
Myelofibrosis
19%
Diseases
18%
Myeloproliferative Neoplasm
18%
Tagraxofusp
15%
Cytarabine
15%
Azacitidine
14%
Ruxolitinib
14%
Clinical Trial
13%
Decitabine
13%
Adverse Event
12%
Leukemia
11%
Acute Lymphoblastic Leukemia
10%
Polycythemia vera
9%
Chronic Myeloid Leukemia
8%
Philadelphia 1 Chromosome
7%
Monotherapy
7%
Malignant Neoplasm
7%
Myeloid Leukemia
7%
Secondary Acute Myeloid Leukemia
6%
Janus Kinase Inhibitor
6%
Ponatinib
6%
Cladribine
6%
Protein Tyrosine Kinase Inhibitor
5%
Chronic Myelomonocytic Leukemia
5%
Hematologic Malignancy
5%
Idarubicin
5%
Dasatinib
5%
Vincristine
5%